ADRM1
ENSG00000130706
Target class
Unclassified protein
Chromosome
20
Approved drugs
3
Clinical candidates (approved and in development)
5
- Approved drugs
- 3
- Clinical candidates (approved and in development)
- 5
- Chemical probe available
- No
- Target name
- ADRM1
- Gene name
- ADRM1 26S proteasome ubiquitin receptor
- Gene symbol
- ADRM1
- Protein name
- Proteasomal ubiquitin receptor ADRM1 (110 kDa cell membrane glycoprotein) (Gp110) (Adhesion-regulating molecule 1) (ARM-1) (Proteasome regulatory particle non-ATPase 13) (hRpn13) (Rpn13 homolog)
- GP110
- Rpn13
- ARM1
- PSMD16
- Gene biotype
- Protein coding
- Gene family
- Proteasome
- Target class
- Unclassified protein
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 175.91
- Tissue specificity (Gini)
- 0.225
- Tissue specificity (tau)
- 0.628
- KEGG gene identifiers
- hsa:11047
- Protein interaction confidence
- 0.913628
- Protein interaction partners
- 78
- R-HSA-1169091
- R-HSA-1234176
- R-HSA-1236974
- R-HSA-1236978
- R-HSA-174084
- R-HSA-174113
- R-HSA-174154
- R-HSA-174178
- R-HSA-174184
- R-HSA-180534
- R-HSA-180585
- R-HSA-187577
- R-HSA-195253
- R-HSA-202424
- R-HSA-211733
- R-HSA-2467813
- R-HSA-2871837
- R-HSA-349425
- R-HSA-350562
- R-HSA-382556
- R-HSA-450408
- R-HSA-4608870
- R-HSA-4641257
- R-HSA-4641258
- R-HSA-5358346
And 42 more, listed on the interactive page.
- End position
- 62308867
- Start position
- 62302066
- Chromosome
- 20
- Strand
- Forward
- Cytoplasm . Nucleus .
- Cytosol
- Nucleoplasm
Publication evidence
- PubMed 16990800
- Tissue specificity (tau)
- 0.627869
- Expression inequality (Gini)
- 0.225078
Expression in transcripts per million
- Testis
- 175.91
- Muscle - Skeletal
- 163.15
- Brain - Cerebellar Hemisphere
- 107.48
- Brain - Cerebellum
- 102.24
- Artery - Tibial
- 94.32
Expression in transcripts per million
- Testis175.91
- Muscle - Skeletal163.15
- Brain - Cerebellar Hemisphere107.48
- Brain - Cerebellum102.24
- Artery - Tibial94.32
- Skin - Sun Exposed (Lower leg)91.25
- Uterus88.92
- Cells - Cultured fibroblasts86.82
- Artery - Coronary85.08
- Cells - EBV-transformed lymphocytes84.91
- Esophagus - Muscularis84.84
- Spleen84.47
- Artery - Aorta84.36
- Lung82.56
- Esophagus - Gastroesophageal Junction82.45
- Skin - Not Sun Exposed (Suprapubic)82.23
- Colon - Sigmoid81.42
- Esophagus - Mucosa80.77
- Fallopian Tube79.89
- Adipose - Subcutaneous78.87
- Nerve - Tibial78.77
- Bladder77.17
- Adrenal Gland74.26
- Vagina73.44
- Breast - Mammary Tissue69.05
And 29 more, listed on the interactive page.
- GO:0006368
- GO:0043248
- GO:0000502
- GO:0005634
- GO:0005654
- GO:0005737
- GO:0005829
- GO:0002020
- GO:0005515
- GO:0061133
- GO:0070628
- GO:0140678
Related records
Trials (789)
- 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
- 3D PET Myocardial Blood Flow and Rb82 Infusion Profiles
- 4SCAR-T Therapy Post CD19-targeted Immunotherapy
- A Basket Study of CTA313 in Participants With Active Autoimmune Diseases
- A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors
- A Clinical Study Evaluating the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Three or More Lines of Treatment
- A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer
- A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
- A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus
- A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors
- A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
- A Clinical Study on the Safety, Tolerance, and Preliminary Efficacy of γδ-T Cell Injection in the Treatment of Advanced Bladder Cancer
- A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
- A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
- A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis
- A First in Human Study to Evaluate the Safety of Infusion of MNV-BM-PLC (Autologous CD34+ Cells Enriched With Placenta Derived Allogeneic Mitochondria) in Patients With Primary Mitochondrial Diseases Associated With Mitochondrial DNA Mutation or Deletion
- A Hypoxia-Inducible CAR-T Cell Targeting AXL and CD73 for Advanced Gastric Cancer
- A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."
- A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type II
- A Multi-site Study of Autologous Cord Blood Cells for Hypoxic Ischemic Encephalopathy
Drugs (5)
- Bortezomib D-mannitol 26S proteasome inhibitor
- Carfilzomib 26S proteasome inhibitor
- Ixazomib 26S proteasome inhibitor
- Ixazomib citrate 26S proteasome inhibitor
- Oprozomib 26S proteasome inhibitor